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Centesimal dilutions (5, 9 and 15 cH) of Gelsemium sempervirens are claimed to be capable of exerting anxiolytic and analgesic
eﬀects. However, basic results supporting this assertion are rare, and the mechanism of action of G. sempervirens is completely
unknown. To clarify the point, we performed a comparative analysis of the eﬀects of dilutions 5, 9 and 15 cH of G. sempervirens or
gelsemine (the major active principle of G. sempervirens) on allopregnanolone (3α,5α-THP) production in the rat limbic system
(hippocampus and amygdala or H-A) and spinal cord (SC). Indeed, H-A and SC are two pivotal structures controlling, respectively,
anxiety and pain that are also modulated by the neurosteroid 3α,5α-THP. At the dilution 5 cH, both G. sempervirens and gelsemine
stimulated [3H]progesterone conversion into [3H]3α,5α-THP by H-A and SC slices, and the stimulatory eﬀect was fully (100%)
reproducible in all assays. The dilution 9 cH of G. sempervirens or gelsemine also stimulated 3α,5α-THP formation in H-A and
SC but the reproducibility rate decreased to 75%. At 15 cH of G. sempervirens or gelsemine, no eﬀect was observed on 3α,5α-THP
neosynthesis in H-A and SC slices. The stimulatory action of G. sempervirens and gelsemine (5 cH) on 3α,5α-THP production
was blocked by strychnine, the selective antagonist of glycine receptors. Altogether, these results, which constitute the first basic
demonstration of cellular eﬀects of G. sempervirens, also oﬀer interesting possibilities for the improvement of G. sempervirens-
based therapeutic strategies.
1. Introduction
Neurons and glial cells are capable of synthesizing various
bioactive steroids also called neurosteroids, which can reg-
ulate the nervous system activity via autocrine or paracrine
mechanisms [1–4]. Pharmacological and behavioral studies
have suggested that neurosteroids are involved in the reg-
ulation of important neurobiological mechanisms [1, 5–7].
In particular, the neurosteroid 3α,5α-tetrahydroprogesterone
(3α,5α-THP), also named allopregnanolone, plays a key
role in the modulation of neurological and psychopatho-
logic symptoms such as depression, anxiety, analgesia and
neurodegeneration [8–13]. 3α,5α-THP is a potent acti-
vator of the central inhibitory transmission, which acts
through allosteric sites located on γ-amino butyric acid
type A (GABAA) receptor [10, 14] or on strychnine-
sensitive glycine receptor (Gly-R) [15, 16]. Because 3α,5α-
THP endogenously synthesized in the central nervous system
significantly modulates anxiety or nociceptive mechanisms
through paracrine and autocrine modes [17–22], substances
which are capable of stimulating 3α,5α-THP formation
in neural networks appear as potentially interesting for
the development of eﬀective anxiolytic or analgesic ther-
apies [23–30]. However, to be therapeutically eﬀective,
the candidate substances must be devoid of side eﬀects
such as nausea, vomiting tolerance, dependence or breath-
ing failure induced by certain anxiolytics and analgesics
[31–34].
For several years, preparations from the yellow jasmine
or Gelsemium sempervirens Loganacea have been claimed
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to be anxiolytic and analgesic medicines but, surprisingly,
scientific results from basic research supporting this assertion
are extremely rare. Indeed, except two studies which showed
that G. sempervirens preparations may prevent stress or
development of spontaneous seizures in vivo [35, 36],
there are no fundamental evidence demonstrating that
G. sempervirens may control neurophysiological processes
such anxiety and pain. In particular, the cellular and
pharmacological mechanisms of action of G. sempervirens
are completely unknown. In our endeavor to clarify this
situation, we have recently investigated the cellular eﬀects
of gelsemine, the major active principle in G. sempervirens
composition, and we observed that gelsemine stimulated
dose-dependently 3α,5α-THP secretion in the rat spinal
cord (SC) through activation of Gly-R [37]. To gain more
insights into the cellular and pharmacological mechanisms
of action of G. sempervirens itself, we have now com-
bined pulse-chase experiments, high-performance liquid
chromatography (HPLC) and flow scintillation detection
[19, 22, 38–42] to perform a comparative analysis of the
eﬀects of G. sempervirens and gelsemine preparations on
[ 3H]progesterone conversion into [ 3H]3α,5α-THP in the
rat limbic system (hippocampus and amygdala or H-A) and
SC. Indeed, the limbic system and SC are well-known for
their crucial roles in the modulation of anxiety and pain,
respectively [43–49]. We have also characterized pharma-
cologically, the main receptor involved in the mediation of
G. sempervirens cellular eﬀects in the limbic system and
SC.
2. Methods
2.1. Animals. Adult male Sprague-Dawley rats weighing
300–350 g were used in this study. Animal care and
manipulations were performed according to the European
Community Council Directives (86/609/EC) and under the
supervision of authorized investigators. All experiments
were performed minimizing the number of animals used
and their suﬀering in accordance with the Alsace Depart-
ment of Veterinary Public Health Guide for the Care and
Use of Laboratory Animals (Agreement number: 67-186).
The animals were obtained from a commercial source
(Janvier, France) and housed under standard laboratory
conditions in a 12-h light/dark cycle with food and water
ad libitum.
2.2. Chemicals and Reagents. Dichloromethane (DCM),
propylene glycol and strychnine hydrochloride were pur-
chased from Sigma-Aldrich (St. Louis, USA). Hexane and
isopropanol were obtained from Fischer Bioblock Scien-
tific (Illkirch, France). The synthesis product gelsemine
came from Extrasynthese (Genay, France). Sodium chloride
(NaCl) was purchased from VWR Prolabo (Fontenay-
sous-Bois, France). Synthetic steroids including PROG,
5α-dihydroprogesterone (5α-DHP) and 3α,5α-THP were
obtained from Steraloids (Newport, USA). Tritiated steroids
such as 1,2,6,7- 3H(N)-progesterone ([ 3H]PROG) and
9,11,12- 3H(N)-3α,5α-tetrahydroprogesterone ([ 3H]3α,5α-
THP) were supplied by PerkinElmer (Boston, USA).
2.3. Preparation of Gelsemine and G. sempervirens Dilutions.
By using a conventional dilution process (pharmacological
dilutions from a stock solution of 1 M of gelsemine), we
have recently observed that gelsemine at 10−10 M stimulated
3α,5α-THP production in the rat SC [37]. Therefore, we
decided to check whether or not gelsemine preparations
obtained by homeopathic procedure (dilutions/dynami-
zations) may conserve the ability to stimulate 3α,5α-THP
formation. Then, we asked Boiron Laboratories to prepare
homeopathic dilutions of gelsemine starting from a hydro-
alcoholic solution (30% ethanol, v/v) of synthetic gelsemine
(purchased from Extrasynthese, Genay France) at 1 M.
Homeopathic dilutions/dynamizations were performed in
cascade with de-ionized water. Consequently, the homeo-
pathic dilutions 5, 9 and 15 cH led theoretically to gelsemine
solution at 10−10, 10−18 and 10−30 M, respectively.
Gelsemium sempervirens preparations were obtained
using the same homeopathic procedure but the mother
tincture was a hydroalcoholic (30% ethanol, v/v) extract of
G. sempervirens plant roots. Gelsemine quantity in G. sem-
pervirens mother tincture was determined by using a quanti-
tative HPLC method [50, 51]. Briefly, 20 μl of G. sempervirens
mother tincture was analyzed on the HPLC column, using
a butylamine/water/methanol (0.1 : 22 : 78 v/v/v) gradient.
Synthetic gelsemine (20 μl), used as reference standard, was
chromatographed under the same conditions and its elution
position as well as the retention time of gelsemine present
in G. sempervirens solution were determined by ultraviolet
absorption at 255 nm. The amount of gelsemine contained
in G. sempervirens was calculated considering areas of the
peaks corresponding to synthetic gelsemine and gelsemine
eluted from G. sempervirens solution. The concentration of
gelsemine estimated from the analyses of diﬀerent samples
of G. sempervirens mother tinctures varied between 5× 10−3
and 5× 10−4 M.
After each dilution step, all gelsemine or G. sempervirens
solutions were agitated at high speed. Control solutions were
prepared according to the same procedure described above,
using only the hydroalcoholic solution (30% ethanol, v/v),
which was submitted to the dilution/dynamization cascade
with de-ionized water. All gelsemine and G. sempervirens
preparations as well as control solutions were kept at 4◦C
before use. Because the dilutions 5, 9 and 15 cH of G.
sempervirens are often used for homeopathic treatments in
humans [52], we decided in agreement with the company
Boiron to focus our eﬀorts on a detailed comparative analysis
of the eﬀects of these three dilutions of gelsemine and G.
sempervirens on allopregnanolone production in H-A and
SC.
2.4. Pulse-Chase Experiments. For each experiment, 200 mg
SC (lumbar segment) or 15 mg H-A slices were preincubated
for 15 min in 1.5 ml of 0.9% NaCl at 37◦C. The SC and
H-A were dissected in rats after deep anesthesia. The SC
was removed by hydraulic extrusion and slices were made
in the lumbar region. SC and H-A slices were incubated at
37◦C for 3 h with 1.5 ml of 0.9% NaCl (pH 7.4) containing
50 nM [ 3H]PROG supplemented with 1% propylene glycol
in the presence of tested compounds. The incubation was
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carried out in a water-saturated atmosphere (95% air, 5%
CO2), which made it possible to maintain the pH at 7.4. At
the end of the incubation period, the reaction was stopped
by adding 500 μl of ice-cold 0.9% NaCl and transferring the
incubation medium in tubes into a cold water bath (0◦C).
Newly-synthesized neurosteroids released in the incubation
medium were extracted three times with 2 ml of DCM, and
the organic phase was evaporated on ice under a stream of
nitrogen. The dry extracts were redissolved in 2 ml of hexane
and prepurified on Sep-Pak C18 cartridges (Waters Asso-
ciates, Milford, USA). Steroids were eluted with a solution
made of 50% isopropanol and 50% hexane. The solvent was
evaporated in a RC-10-10 Speed Vac Concentrator and the
dry extracts were kept at −20◦C until HPLC analysis. The
extraction eﬃciency was 89± 7%.
2.5. HPLC-Flo/One Characterization of Steroids. The newly
synthesized steroids extracted from the incubation medium
already purified on Sep-Pak cartridges were characterized
using a previously validated method which combines HPLC
analysis and flow scintillation detection [19, 22, 38–42].
Briefly, the prepurified extracts were analyzed by reversed-
phase HPLC on a liquid chromatograph (322 pump, UV/VIS
156 detector, Unipoint system; Gilson, Middleton, USA)
equipped with a 4.6 × 250 mm SymetryShield C18 column
(Waters Associates, Milford, USA) equilibrated with 100%
hexane. The radioactive steroids were eluted at a flow rate
of 0.5 ml min−1 using a gradient of isopropanol (0%–60%
over 65 min) including five isocratic steps at 0% (0–10 min),
1% (30–35 min), 2% (40–45 min), 30% (50–55 min) and
60% (60–65 min). The tritiated steroids eluted from the
HPLC column were directly quantified with a flow scintil-
lation analyzer (Radiomatic Flo/One-Beta A 500; Packard
Instruments, Meriden, USA) equipped with a Pentium
IV PC computer (Dell-Computer-France, Lyon, France)
for measurement of the percentage of total radioactivity
contained in each peak. Synthetic steroids used as reference
standards were chromatographed under the same conditions
as the extracts obtained from the incubation media and their
elution positions were determined by ultraviolet absorption
using a UV/VIS 156 detector (Gilson, Middleton, USA). The
elution positions of steroids change on analytic columns
after the purification of a certain number of tissue extracts.
Therefore, to optimize the characterization of newly synthe-
sized neurosteroids, synthetic tritiated neuroactive steroids
including [ 3H]PROG and [ 3H]3α,5α-THP were also used
as reference standards, chromatographed under the same
conditions as the extracts and identified by their elution
times with the Flo/One computer system before and after
each extract analytic run.
2.6. Quantification of 3α,5α-THP Released by the SC and H-A
Slices and Statistical Analysis. The amount of [ 3H]3α,5α-
THP newly synthesized from [ 3H]PROG and released by
H-A or SC slices in the incubation medium was expressed
as a percentage of the total radioactivity contained in all
peaks resolved by the HPLC-Flo/One system (after analysis
of the incubation medium extracts), including [ 3H]PROG
itself. Each value presented is the mean (±SEM) of four
independent experiments. Statistical analysis was performed
with the 3.05 version of GraphPad Instat (GraphPad Software
Inc., San Diego, CA, USA). The statistical significance of
diﬀerences between two groups was assessed with Student’s t-
test. Analysis of variance (ANOVA) followed by Bonferroni’s
test was applied for multi-parameter analyses. A P-value of
less than 0.05 was considered significant.
3. Results
3.1. Eﬀects of Gelsemine and G. sempervirens Preparations
on 3α,5α-THP Production in the SC and H-A. A 3-h
incubation of lumbar SC slices with [ 3H]PROG yielded
the formation of various radioactive metabolites (Figures
1(a)–1(c)). Reversed-phase HPLC analysis coupled with
flow scintillation detection made it possible to resolve
two major radioactive metabolites coeluting with [ 3H]5α-
dihydroprogesterone ([ 3H]5α-DHP) and [ 3H]3α,5α-THP
(Figures 1(a)–1(c)). The conversion of [ 3H]PROG into
[ 3H]5α-DHP and [ 3H]3α,5α-THP was also observed in H-
A (limbic system) slices with the same chromatographic
profile as this shown in Figure 1. Investigations of the
eﬀects of gelsemine and G. sempervirens on [ 3H]3α,5α-
THP neosynthesis in SC and H-A slices were performed
by testing the dilutions 5, 9 and 15 cH. At the dilution
5 cH, gelsemine and G. sempervirens preparations were able
to stimulate significantly [ 3H]progesterone conversion into
[ 3H]3α,5α-THP in SC (Figure 2) and H-A (Figure 3).
The stimulatory eﬀect of geslmine or G. sempervirens at
5 cH was fully (100%) reproducible since the same eﬀect
was observed in all intra- and inter-assays performed. At
the dilution 9 cH, a stimulatory action of gelsemine or
G. sempervirens was detected on 3α,5α-THP production in
SC and H-A slices (Figures 2 and 3] but this eﬀect was
observed only in 75% of the total number of samples in intra-
and inter-assays investigations. No eﬀect was detected when
gelsemine and G. sempervirens preparations were applied at
the dilution 15 cH. In the SC, G. sempervirens or gelsemine
at 5 cH induced, respectively, a 547% or 193% increase
of [ 3H]3α,5α-THP neosynthesis from [ 3H]progesterone
(Figures 2(a) and 2(b)). In the limbic system or H-A, G.
sempervirens or gelsemine at 5 cH generated, respectively, a
178% or 94% enhancement of [ 3H]3α,5α-THP formation
(Figures 2(a) and 2(b)).
3.2. Comparative Analysis of the Stimulatory Capacity of
Gelsemine and G. sempervirens on 3α,5α-THP Biosynthe-
sis. In the SC, G. sempervirens preparations produced a
stronger stimulation of 3α,5α-THP formation than gelsem-
ine. Indeed, the level of [ 3H]3α,5α-THP newly synthesized
in the presence of G. sempervirens at 5 cH was 1.7-fold higher
than in the presence of gelsemine at 5 cH (Figure 4).
In the limbic system or H-A slices, G. sempervirens
at 5 cH increased 3α,5α-THP production 1.5-fold than
gelsemine at 5 cH (Figure 5).
3.3. Pharmacological Characterization of the Receptor Mediat-
ing the Eﬀects of Gelsemine and G. sempervirens Preparations
on 3α,5α-THP Biosynthesis in the SC and H-A. On the basis
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Figure 1: Characterization of [ 3H]-neurosteroids released in the incubation medium by: (a) lumbar SC slices after a 3-h incubation with
[ 3H]PROG in the absence (b) or in presence of gelsemine 5 cH or (c) Gelsemium sempervirens 5 cH. Analyses were performed using a
hexane/isopropanol gradient and a reverse-HPLC system coupled to a flow scintillation detector. The ordinate indicates the radioactivity
measured in the HPLC eluent. The dashed line represents the gradient of secondary solvent (% isopropanol). The arrows indicate elution
positions of standard steroids.
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Figure 2: Eﬀects of gelsemine (a) and G. sempervirens (b) at 9 or 5 cH on 3α,5α-THP production by SC slices. Each value was calculated
as the relative amount of [ 3H]3α,5α-THP compared with the total [ 3H]-labeled compounds resolved by HPLC-Flo/One characterization
(×100). The values were obtained from experiments similar to those presented in Figures 2(a). Results were then expressed as percentages
of the amount of [ 3H]3α,5α-THP formed in absence of gelsemine or G. sempervirens (control). Each value is the mean (± SEM) of four
independent experiments. ∗∗P < .01, ∗∗∗P < .001 as compared to control (Student’s t-test).
of our previous observations about synthetic gelsemine
[37], we investigated whether or not strychnine-sensitive
Gly-R may be involved in the mediation of the eﬀects of
G. sempervirens and gelsemine preparations obtained by
homeopathic procedure (Figures 6 and 7). In a first step,
we performed pulse-chase/HPLC-Flo/One experiments in
the presence of various concentrations of strychnine, the
well-known selective antagonist of Gly-R; we observed that
strychnine at 10−5 or 10−6 M was completely devoid of
action on the formation of [ 3H]3α,5α-THP in the SC or
H-A, respectively (Figures 6 and 7). In addition, we found
that the stimulatory eﬀect exerted by gelsemine (5 cH) or
G. sempervirens (5 cH) on [ 3H]3α,5α-THP production in
the SC was completely antagonized by strychnine at 10−5 M
(Figures 6(a) and 6(b)). Similarly, in the limbic system or H-
A slices, increase of [ 3H]3α,5α-THP neosynthesis induced by
gelsemine (5 cH) or G. sempervirens (5 cH) was completely
blocked by strychnine (10−6 M) (Figures 7(a) and 7(b)).
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Figure 3: Eﬀects of gelsemine (a) and G. sempervirens (b) at 9 or 5 cH on 3α,5α-THP production by H-A slices. The values were obtained
from experiments similar to those presented in Figure 1. Results were then expressed as percentages of the amount of [ 3H]3α,5α-THP
formed in the control group. Each value is the mean (±SEM) of four independent experiments. ∗P < .05, ∗∗∗P < .001 as compared to
control (Student’s t-test).
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Figure 4: Comparative analysis of the eﬀects of gelsemine and
G. sempervirens at 9 or 5 cH on [ 3H]PROG conversion into
[ 3H]3α,5α-THP by SC slices. The values were obtained from
experiments similar to those presented in Figure 1. Results were
then expressed as percentages of the amount of [ 3H]3α,5α-THP
formed in the control group. Each value is the mean (±SEM) of
four independent experiments. ∗P < .05, ∗∗∗P < .001 as compared
to control; #P < .05, ##P < .01 as compared to gelsemine (ANOVA
followed by Bonferroni’s test).
4. Discussion
This article provides the first basic evidence supporting the
existence of cellular eﬀects of G. sempervirens preparations
in the limbic system and SC. In addition, the work made
possible the identification of pharmacological mechanisms
involved in the mediation of G. sempervirens and gelsemine
action in H-A and SC slices. Thanks to a well-validated
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Figure 5: Comparative analysis of the eﬀects of gelsemine and
G. sempervirens at 9 or 5 cH on [ 3H]PROG conversion into
[ 3H]3α,5α-THP by H-A slices. The values were obtained from
experiments similar to those presented in Figure 1. Results were
then expressed as percentages of the amount of [ 3H]3α,5α-THP
formed in absence of gelsemine and G. sempervirens (control). Each
value is the mean (± SEM) of four independent experiments. ∗P <
.05, ∗∗∗P < .001 as compared to control; ##P < .01 as compared to
gelsemine (ANOVA followed by Bonferroni’s test).
approach combining pulse-chase experiments with HPLC
analysis and continuous flow scintillation detection [19, 22,
38–42], we observed that gelsemine and G. sempervirens at
5 cH significantly stimulated [ 3H]progesterone conversion
into [ 3H]3α,5α-THP in H-A (limbic system) and SC slices.
At the dilution 9 cH, a stimulatory action of gelsemine and
G. sempervirens was also detected on 3α,5α-THP production
in the SC and H-A but the reproducibility rate was limited
at 75%. This observation suggests the existence of instability
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Figure 6: Eﬀects of gelsemine (a) or G. sempervirens (b) at 5 cH on
[ 3H]3α,5α-THP production by SC slices in the absence or presence
of strychnine (10−5 M), the specific glycine receptor antagonist. The
values were obtained from experiments similar to those presented in
Figure 1. Results were then expressed as percentages of the amount
of [ 3H]3α,5α-THP formed in the control group. Each value is the
mean (±SEM) of four independent experiments. ∗∗∗P < .001 as
compared to gelsemine; ##P < .01, ###P < .001 as compared to G.
sempervirens (ANOVA followed by Bonferroni’s test). NS represents
not statistically diﬀerent.
or the lack of homogeneity of high diluted homeopathic
solutions. In agreement with this hypothesis, there was no
linearity of the stimulatory eﬀects induced by gelsemine or
G. sempervirens at 5 and 9 cH contrary to what is usually
observed in conventional pharmacology for dose-response
studies. Neurosteroid 3α,5α-THP possesses an important
therapeutical potential owing to its key role in the regulation
of cellular mechanisms involved in anxiety, pain, depression
and neurodegeneration [4, 9, 10, 12, 13]. In particular, it
has clearly been shown that the endogenous conversion of
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Figure 7: Eﬀects of (a) gelsemine or (b) G. sempervirens at 5 cH on
3α,5α-THP production by H-A slices in the absence or presence of
strychnine (10−6 M). The values were obtained from experiments
similar to those presented in Figure 1. Results were then expressed
as percentages of the amount of [ 3H]3α,5α-THP formed in the
control group. Each value is the mean (±SEM) of four independent
experiments. ∗∗∗P < .001 as compared to gelsemine; ##P < .01,
###P < .001 as compared to G. sempervirens (ANOVA followed by
Bonferroni’s test). NS represents not statistically diﬀerent.
progesterone into 3α,5α-THP in the limbic system is crucial
for the expression of anxiolytic eﬀect of progesterone [9, 20,
21, 53]. Moreover, we have recently demonstrated that 3α,5α-
THP endogenously synthesized in SC exerts a key analgesic
action in animals subjected to sciatic nerve injury-induced
neuropathic pain [18, 19]. Therefore, it appears that the
stimulatory eﬀect exerted by G. sempervirens or gelsemine
preparations on 3α,5α-THP production in H-A or SC may
reflect cellular mechanisms activated by these preparations
to induce anxiolytic or analgesic eﬀects. In support of this
hypothesis, the presence and activity of 3α-hydroxysteroid
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Figure 8: Eﬀect of gelsemine (5 cH) or G. sempervirens (5 cH) on 3α,5α-THP production in the SC and H-A. (1) Gelsemine (5 cH) or G.
sempervirens (5 cH) stimulated [ 3H]progesterone conversion into [ 3H]3,5-THP in SC and H-A slices. (2) Strychnine, the selective antagonist
of glycine receptors (Gly-R), totally blocked the stimulatory eﬀect of gelsemine (5 cH) or G. sempervirens (5 cH) on 3α,5α-THP production.
(3) Further investigations are required for the identification of intracellular mechanisms triggered by gelsemine (5 cH) or G. sempervirens
(5 cH) from Gly-R. However, the stimulatory action exerted by gelsemine (5 cH) or G. sempervirens (5 cH) on 3α,5α-THP production
suggests that the intracellular cascade activated by these substances may increase the activity of 3α-HSOR which is the key 3α,5α-THP-
synthesizing enzyme. [4, 5] Neurosteroid 3α,5α-THP newly synthesized by neurons or glial cells in the SC or H-A may modulate GABAA-R
or Gly-R through autocrine (4) or paracrine (5) mechanisms leading to analgesic and/or anxiolytic eﬀects of G. sempervirens.
dehydrogenase or 3α-HSOR (the key enzyme synthesizing
3α,5α-THP) has been evidenced in the limbic system and
spinal circuit, suggesting that G. sempervirens and gelsemine
may increase 3α,5α-THP formation through stimulation of
3α-HSOR enzymatic activity in H-A and SC neural net-
works [18, 54–56]. Furthermore, it has been demonstrated
that the limbic and spinal systems, two pivotal structures
modulating respectively anxiety and pain sensation, contain
several populations of nerve cells expressing Gly-R [43, 44,
46–48, 57–60]. Consistently, our pharmacological analyses
revealed that strychnine, the selective antagonist of Gly-
R [58, 59], completely blocked the stimulatory eﬀect of
gelsemine and G. sempervirens on 3α,5α-THP production
in H-A and SC slices. Taken together, these results show
that gelsemine (5 cH) and G. sempervirens (5 cH), acting
through Gly-R located on H-A and SC nerve cells, may
stimulate 3α-HSOR enzymatic activity, which, in turn,
may increase 3α,5α-THP production in the limbic system
and spinal circuit. Our data and hypothesis are summa-
rized and illustrated by the general diagram presented in
Figure 8.
The comparative analyses also revealed that the stimula-
tory capacity of G. sempervirens on 3α,5α-THP biosynthesis
in H-A and SC slices seems higher than that of gelsemine.
Indeed, the theoretical estimation of gelsemine quantity in
G. sempervirens mother tincture made after HPLC analysis
showed that the tincture contains a concentration less than
1 M. Significant diﬀerences are observed between samples of
mother tinctures but it appeared that the initial gelsemine
concentration in G. sempervirens mother tincture may
not be higher than 5× 10−3 M. Additional analyses such
as mass spectrometry quantification after HPLC or gaz
chromatographic purification will certainly help in the future
to determine the accurate concentration of gelsemine in
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G. sempervirens mother tincture. However, based on the esti-
mation performed herein, gelsemine at 5 cH (prepared from
synthetic gelsemine stock solution at 1 M) may correspond
to 10−10 M while G. sempervirens at 5 cH (prepared from the
mother tincture) may contain a concentration of gelsemine
within 5× 10−14 M and 5× 10−13 M. Because G. semper-
virens at 5 cH increased 3α,5α-THP production 1.5- to 1.7-
fold than gelsemine at 5 cH, it is possible to speculate
that a positive synergism exists between gelsemine and
other constituents present in G. sempervirens composition
such as sempervirine, gelsemicine and gelsenicine [61–63].
Whether all constituents of G. sempervirens also modulate
Gly-R like gelsemine [37] remains a matter of speculation.
Future investigations will answer this question even though
pharmacological analyses described herein revealed that the
stimulatory action of G. sempervirens (5 cH) was totally (not
partially) blocked by strychnine.
At the dilution 9 cH, gelsemine and G. sempervirens
exerted a stimulatory action on 3α,5α-THP production but
the eﬀect was not reproducible in all intra- and inter-assays
performed. However, because the stimulatory eﬀect was
observed in 75% of the total number of samples analyzed, it
appears that high dilutions of G. sempervirens may conserve
interesting bioactivity. Therefore, it seems reasonable to
expect only a few or no side eﬀects from G. sempervirens-
based therapeutical strategies. Indeed, even if the results
obtained with the dilution 9 cH may not be exploitable
because of the limited reproducibility, therapeutic strategies
may be achieved with G. sempervirens at 5 cH which remains
a very low concentration that exhibited a full (100%)
reproducible eﬀect on 3α,5α-THP production in SC and
H-A.
In conclusion, the results provided herein may constitute
key basic knowledge on cellular and pharmacological eﬀects
of G. sempervirens and gelsemine preparations. The data may
also open new possibilities for the improvement of current
therapeutical utilization of G. sempervirens which refers only
to empirical knowledge but not to fundamental evidence
supplied by basic research.
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